News & Information
CoM3D features in Guardian Newspaper article
Global mega-trends influencing the future of healthcare...
PharmE3D Labs Earn Multiple Pharmaceutical Science Distinctions
The University of Texas at Austin College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) labs, led by...
3D Printing In Personalized Drug Delivery
3D printing is set to revolutionise the development, manufacture and delivery of vaccines and therapeutics...
CoM3D and University of Texas at Austin sign patent license agreement
The University of Texas at Austin and CoM3D Limited, a company focused on commercialization of advanced drug manufacturing and...
CoM3D Secures up to £1M in New Funding
CoM3D is very pleased to announce the successful closing of a recently announced financing round, having secured up to £1M...
CoM3D developing hybrid anti-viral delivery systems
CoM3D is pleased to announce its work on the development of hybrid anti-viral nanoparticulate delivery systems, has commenced, at the University of Texas...
Maniruzzaman Lab collaboration works to develop patient-focused medicines more efficiently
In an effort to address challenges with the reduction in quantity of new drugs coming to market, a team of pharmaceutical scientists...
CoM3D appoints Alastair Syvret to Advisory Panel
CoM3D are pleased to announce the appointment of Alastair Syvret to it's Advisory Panel. From 1995 to 2018 Alastair was a partner of...
CoM3D launches Funding Round
CoM3D is delighted to announce the launch of a funding round to enable larger scale funding of its R&D efforts at the University of Texas at Austin...
CoM3D appoints Dr Anthony Thomson as CEO
CoM3D are delighted to announce the appointment of Dr Anthony Thomson MSc MBA PhD FRSM as CEO of the company which is working...
Video Highlights
3D Printing of thin film, smart biomaterials
Rapidly Dissolving PortaPill
Latest News...
> PharmE3D Labs Earn Multiple Pharmaceutical Science Distinctions
> 3D Printing In Personalized Drug Delivery
> CoM3D and University of Texas at Austin sign patent license agreement
> CoM3D Secures up to £1M in New Funding
> CoM3D developing hybrid anti-viral delivery systems
> Maniruzzaman Lab collaboration works to develop patient-focused medicines more efficiently
> CoM3D appoints Alastair Syvret to Advisory Panel
> CoM3D appoints Dr Anthony Thomson as CEO.
© 2024 CoM3D Limited | Privacy Policy